Drug eases GVHD symptoms in patients who had stem cell transplant

12/1/2011 | U.S. News & World Report

Daily, low-dose injections of interleukin-2 eased symptoms of graft-versus-host disease, or GVHD, in cancer patients who underwent allogeneic hematopoietic stem cell transplantation, according to a study published in the New England Journal of Medicine. Of 23 patients given the drug for eight weeks, 12 showed improvement, according to the study.

View Full Article in:

U.S. News & World Report

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Claims Director
PacificSource
Springfield, OR
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA